Omnitrope pen 75iu kit – 5 x 10mg(15iu) 1.5ml HGH cartridges is a recombinant somatropin Human Growth Hormone manufactured by Sandoz Pharmaceuticals, US. It is mainly prescribed by doctors to adults with growth hormone deficiency (AGHD) and elderly patients with age-related hormone imbalance for anti-aging purposes. It is supplied in a pack of 5 x 1.5ml/5mg(15iu) or 5 x 1.5ml/10mg(30iu) using convenient cartridges and a pen device for administration.
In paediatrics, Omnitrope pen is prescribed for children with growth failure due to growth hormone deficiency (GHD) and Prader-Willi syndrome (diagnosed by genetic testing). It is also indicated for the treatment of SGA – growth failure in children born small for gestational age, failing to catch-up growth by the age of 2, as well as for children that do not grow due to idiopathic short stature (with no known cause) and ones suffering from Turner Syndrome (females with only a single X chromosome). In adults, Omnitrope is used to treat adult onset or childhood onset growth hormone deficiency.
Omnitrope hgh is contraindicated in children:
– With acute critical illnesses,
– With respiratory failure,
– With cancer/ active malignancy,
– With active proliferative or nonproliferative diabetic retinopathy,
– With known hypersensitivity to somatropin,
– With closed epiphyseal plates,
– Who are severely obese or with respiratory impairment with Prader-Willi Syndrome,
– After trauma,
Before prescribing Omnitrope, doctor should look out for the following:
– Signs of upper airway obstruction and sleep apnoea in children with Prader-Willi Syndrome; if any symptoms arise – treatment should be discontinued;
– Neoplasm: patients with pre-existing tumours should be monitored for progression or recurrence; childhood cancer survivors if treated with somatropin, hold the increased risk of a second neoplasm, especially meningiomas in those treated with radiation to the head for their first neoplasm;
– Glucose levels should be monitored in all patients; in diabetic patients, dosage of concurrent anti-hyperglycaemic may require adjustment as impaired glucose tolerance and diabetes mellitus may get unmasked;
– Intracranial Hypertension may develop; can be reversed by reducing the dose or terminating the treatment;
– Fluid retention – frequent in adults, like oedema, arthralgia or carpal tunnel syndrome. Dose reduction is required in such cases;
– Other hormone replacement therapies should be monitored closely due to an increased risk for hypopituitarism;
– Hypothyroidism can become evident or get worse;
– Children with the onset of a limp or hip/knee pain should be evaluated for slipped capital femoral epiphysis
– Pre-existing scoliosis may worsen
– Pancreatitis should be considered in patients with persistent severe abdominal pain;
Formulations containing BA (benzyl alcohol) should not be used in premature babies or neonates (e.g., 5 mg/1.5 mL Omnitrope + Bacteriostatic Water diluent for the Omnitrope pen. Once the treatment is started, risks of continuing Omnitrope pen should be considered if the child has any of the following: scoliosis, diabetes, cancer, hormone deficiencies, trauma, complains about hip or knee pains, limping, or difficulty breathing. Tests for child’s blood glucose and funduscopic examination (an eye test for intracranial hypertension) must be performed before starting the treatment and periodically afterwards. Parents of children, who are treated for Prader-Willi syndrome and start having difficulty breathing, start snoring or their snoring increases, should seek medical advice.
Side effects that may arise after the treatment with Omnitrope pen include headaches, loss of fatty tissue under the skin (lipoatrophy) or rash at the injection sites.
Some medication may interact with Omnitrope pen :
– The enzyme 11β-hydroxysteroid dehydrogenase type 1 (11βHSD-1) is required for cortisol production in liver and fatty tissue; growth hormone inhibits 11βHSD-1 which in people with GH deficiency may result in increased serum cortisol; these may require the initiation of glucocorticoid replacement therapy;
– Glucocorticoid replacement dosing should be adjusted in children who receive concomitant somatropin and glucocorticoid therapies;
– Cytochrome P450-metabolized drugs should be monitored carefully if used with somatropin; some data suggest that somatropin administration could alter the clearance of compounds metabolized by CYP450 liver enzymes (like sex steroids, corticosteroids, anticonvulsants, cyclosporine, etc.);
– In women undergoing oral oestrogen replacement therapy, larger doses of somatropin may be required;
– Insulin or oral hypoglycemic agents may require adjustment in diabetes mellitus patients;
Administration of Omnitrope using Pen 5 is easy: it delivers a maximum single dose of 2.7 mg in increments of 0.05 mg. It is given as an injection each day or several times a week.
Pen uses prefilled liquid cartridges what eliminates the need to mix or reconstitute the medication, and enables the user to give the correct dose and avoid wasting or spilling. Pen doesn’t need batteries or rewinding, thus it eliminates steps and saves user’s time.